Forward QI-Module 9: FDA-Approved Anti-Obesity Medications for Chronic Weight Management

Video Transcription

Video Summary

Dr. Octavia Pickett-Blakely reviews FDA-approved anti-obesity medications as long-term adjuncts to diet and physical activity for chronic weight management in patients with obesity or overweight plus comorbidities. She explains that obesity is driven by abnormal neurohormonal homeostatic pathways affecting energy intake and expenditure, and medications target these CNS and/or peripheral pathways to reduce appetite and improve complications. Even 0–5% weight loss can improve hypertension and hyperglycemia; larger losses (5–15%+) yield greater benefits, including improved cardiovascular risk, sleep apnea, MASH, and possible diabetes remission. She summarizes mechanisms, efficacy, and safety for key agents: tirzepatide (dual GIP/GLP-1; ~21% mean loss in SURMOUNT), semaglutide (~15% in STEP; cardiovascular benefit shown), liraglutide (~7.5%), naltrexone-bupropion (~6.4%), phentermine-topiramate ER (~11%), orlistat (peripheral lipase inhibitor; ~9.6%), and phentermine (~7.4%). Key cautions include GI effects for incretin agents, thyroid tumor warnings (GLP-1/GIP agents), pregnancy contraindications (liraglutide, phentermine-topiramate, orlistat), seizure and opioid-related contraindications (naltrexone-bupropion), and cardiovascular risks/abuse potential (phentermine).

Meta Tag

Domain Healthcare Administration

Profession Physician

Subject Matter Preventative Care

Keywords

FDA-approved anti-obesity medications

chronic weight management

GLP-1/GIP incretin therapies (semaglutide, tirzepatide, liraglutide)

weight loss efficacy and cardiometabolic benefits

mechanisms of obesity neurohormonal pathways (appetite/energy expenditure)

safety contraindications and adverse effects (GI, thyroid warning, pregnancy, cardiovascular risk)

Healthcare Administration

Physician

Preventative Care